Regulated information

SALES 1st quarter 2024: €134M

The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products.

Availability of the 2023 universal registration document

On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).

BALO : Notice of meeting

Shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 28, 2024 at 11 a.m. at the Company's registered office, Magny-Vernois 70 200 LURE, in order to deliberate on the following agenda and draft resolutions

2023 ANNUAL RESULTS

Annual sales: €529m (stable at constant exchange rates)
Essentials sales: €313m (+4.5% at constant exchange rates)
Net income - Group share: €56m (10.5% of sales)
EBITDA: €113m (21.3% of sales)
Free cash-flow: €89m

Annual sales 2023: €529 million

Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates)

Forcyl® - a booming brand

Lure (France), November 14, 2012 – Vétoquinol receives a new indication for its Forcyl® product, designed for cattle, and a new market authorization for Forcyl® Swine for pigs.

Sales momentum continues in Q3

Vétoquinol posted sales of €220.9 million for the first 9 months of 2012, up 6.2% compared to the same period last year.

Vétoquinol purchases ORSCO laboratoire vétérinaire

Lure (France), September 25, 2012 – Vétoquinol announces the purchase of the entire equity of Orsco Laboratoire Vétérinaire.

Vétoquinol returns to growth

Lure (France), 29 August 2012 – At its 29 August 2012 meeting, the Vétoquinol S.A. board of directors reviewed the Group results and approved the financial statements for the first six months of 2012.

Solid first half 2012 Sales

First half 2012 sales reached €146.8 million, up 5.1% over first half 2011.